Metabotropic Glutamate Receptors Type 3 and 5 Feature the “NeuroTransmitter-type” of Glioblastoma: A Bioinformatic Approach

Title:Metabotropic Glutamate Receptors Type 3 and 5 Feature the “NeuroTransmitter-type” of Glioblastoma: A Bioinformatic Approach

Volume: 22 Issue: 11

Author(s): Matteo Caridi, Marika Alborghetti, Valeria Pellicelli, Rosamaria Orlando, Francesco Ernesto Pontieri, Giuseppe Battaglia*Antonietta Arcella

Affiliation:

• Department of Physiology and Pharmacology, University Sapienza of Roma, Rome, Italy
• IRCCS Neuromed, Pozzilli, Italy

Keywords: Glioma, glioblastoma multiforme, metabotropic glutamate receptors type 3 and type 5, glutamate, neurotransmitter- GBM, immunological signature, metabolic signature.

Abstract:

Background: Glioblastoma (GBM) represents an aggressive and common tumor of the central nervous system. The prognosis of GBM is poor, and despite a refined genetic and molecular characterization, pharmacological treatment is largely suboptimal.

Objective: Contribute to defining a therapeutic line in GBM targeting the mGlu3 receptor in line with the principles of precision medicine.

Methods: Here, we performed a computational analysis focused on the expression of type 3 and 5 metabotropic glutamate receptor subtypes (mGlu3 and mGlu5, respectively) in high- and low-grade gliomas.

Results: The analysis allowed the identification of a particular high-grade glioma type, characterized by a high expression level of both receptor subtypes and by other markers of excitatory and inhibitory neurotransmission. This so-called neurotransmitter-GBM (NT-GBM) also shows a distinct immunological, metabolic, and vascularization gene signature.

Conclusion: Our findings might lay the groundwork for a targeted therapy to be specifically applied to this putative novel type of GBM.

Cite this article as:

Caridi Matteo, Alborghetti Marika, Pellicelli Valeria, Orlando Rosamaria, Pontieri Ernesto Francesco, Battaglia Giuseppe*, Arcella Antonietta, Metabotropic Glutamate Receptors Type 3 and 5 Feature the “NeuroTransmitter-type” of Glioblastoma: A Bioinformatic Approach, Current Neuropharmacology 2024; 22 (11) . https://dx.doi.org/10.2174/1570159X22666240320112926